<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27738" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Primary Sclerosing Cholangitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rawla</surname>
            <given-names>Prashanth</given-names>
          </name>
          <aff>Sovah Health, Martinsville, VA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samant</surname>
            <given-names>Hrishikesh</given-names>
          </name>
          <aff>Ochsner Multiorgan Transplant Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prashanth Rawla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hrishikesh Samant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27738.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disorder of unknown etiology. Inflammation, fibrosis, and stricturing of intrahepatic or extrahepatic biliary ducts characterize PSC. PSC is usually a progressive disorder that leads to complications of cholestasis and liver failure. Median survival from the time of diagnosis to death without liver transplantation is around 10 years. This activity reviews the etiology, pathogenesis, evaluation, and management of primary sclerosing cholangitis and explains the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the epidemiology of primary sclerosing cholangitis.</p></list-item><list-item><p>Assess&#x000a0;how to evaluate for primary sclerosing cholangitis.</p></list-item><list-item><p>Evaluate the management options available for primary sclerosing cholangitis.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination&#x000a0;to improve outcomes for patients affected by primary sclerosing cholangitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27738&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27738">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27738.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disorder of unknown etiology. PSC is characterized by inflammation, fibrosis, and stricturing of intrahepatic or extrahepatic biliary ducts.<xref ref-type="bibr" rid="article-27738.r1">[1]</xref>&#x000a0;PSC is usually a progressive disorder that leads to complications of cholestasis and liver failure. Median survival from the time of diagnosis to death without liver transplantation is around 10 years.<xref ref-type="bibr" rid="article-27738.r2">[2]</xref>&#x000a0;The established subtypes of PSC are:</p>
        <list list-type="order">
          <list-item>
            <p><italic toggle="yes">Classic:</italic> Affects small and large bile ducts</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Small-duct:</italic> Affects only small bile ducts</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Associated with autoimmune hepatitis:</italic>&#x000a0;Affects small and large bile ducts<xref ref-type="bibr" rid="article-27738.r3">[3]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>PSC is linked to ulcerative colitis and may be complicated by the onset of cholangiocarcinoma. Over the past few decades, endoscopic retrograde cholangiopancreatography (ERCP) has led to more recognition of this disorder. There is no cure for PSC, which is managed with ursodeoxycholic acid. Some patients end up with a liver transplant, but then they have to deal with an immunosuppressed state and its associated complications.</p>
      </sec>
      <sec id="article-27738.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;PSC is not understood; however, genetic and environmental factors contribute to its development.<xref ref-type="bibr" rid="article-27738.r3">[3]</xref>&#x000a0;Inflammatory bowel disease&#x000a0;(IBD)&#x000a0;is considered to be a significant risk factor for the development of PSC.<xref ref-type="bibr" rid="article-27738.r4">[4]</xref> About 60% to 80% of patients with PSC have IBD (predominantly ulcerative colitis in about 80% and Crohn&#x000a0;disease in 20%), and about 5% to 10% of patients with ulcerative colitis have coexisting PSC.<xref ref-type="bibr" rid="article-27738.r5">[5]</xref>&#x000a0;PSC is believed to be an autoimmune disorder. Some patients have elevated levels of antineutrophilic cytoplasmic antibodies, antinuclear antibodies, and anticardiolipin antibodies. In addition, individuals with HLA B8 and HLA DR3 genes are at a higher risk of developing the disorder.</p>
      </sec>
      <sec id="article-27738.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence rates for&#x000a0;PSC range from 0 to 1.3 per 100,000 inhabitants/year, and&#x000a0;prevalence rates are 0 to 16.2 per 100,000 inhabitants.<xref ref-type="bibr" rid="article-27738.r6">[6]</xref>&#x000a0;PSC incidence and prevalence are higher in North America and Northern Europe than in Asia. Patients are&#x000a0;diagnosed between the ages of 30 and 40 years. The median age at the diagnosis of PSC was 41 years. PSC is more common in men (65% to 70%), and males have a 2-fold increased risk of developing PSC when compared to females.<xref ref-type="bibr" rid="article-27738.r7">[7]</xref>&#x000a0;The relative risk of&#x000a0;PSC among siblings with the disease is 9 to 39 times&#x000a0;higher&#x000a0;when compared to the risk in the general population.&#x000a0;A distinct feature is that PSC is commonly observed in nonsmokers.</p>
      </sec>
      <sec id="article-27738.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PSC is characterized by inflammation, fibrosis, and cholestasis.&#x000a0;Hereditary and environmental factors play a role in the pathogenesis of PSC. Healthcare researchers&#x000a0;hypothesize that after&#x000a0;exposure to an unidentified environmental source, persistent injury of the cells lining the bile ducts&#x000a0;(cholangiocytes) occurs via several genetically predisposed pathways.<xref ref-type="bibr" rid="article-27738.r8">[8]</xref>&#x000a0;A large cohort genome-wide association study showed a strong association with specific human leukocyte antigens (HLA).<xref ref-type="bibr" rid="article-27738.r9">[9]</xref>&#x000a0;PSC&#x000a0;is strongly associated with HLA class 1, 2, and 3 regions (ie, HLA-B*08, HLA-DRB1 alleles, and a locus near&#x000a0;<italic toggle="yes">NOTCH4</italic>, respectively).<xref ref-type="bibr" rid="article-27738.r8">[8]</xref> Inflammation and fibrosis lead to cholestasis and&#x000a0;parenchymal injury. Biliary obstruction might facilitate&#x000a0;cholangitis.<xref ref-type="bibr" rid="article-27738.r10">[10]</xref>&#x000a0;Biliary scarring leads to portal hypertension, which causes venous compression in the portal triads. PSC is a premalignant disease, as 10% to 20% of patients with PSC develop cholangiocarcinoma. PSC-induced cholangiocarcinoma is thought to be&#x000a0;inflammation-induced&#x000a0;cancer contributed by the toxic environment of bile, which acts as a cofactor in accelerating carcinogenesis. Genetic and immune factors&#x000a0;may play an important role.</p>
      </sec>
      <sec id="article-27738.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Progressive fibrosis around intrahepatic bile ducts leads to concentric and circumferential laminations called "onion skin" fibrosis. This leads to the displacement of the pre-biliary capillary plexus and creates a barrier to oxygenation&#x000a0;and maintenance of cholehepatic countercurrent circulation between the artery and the bile duct. Arterial or capillary ischemia is involved in stricturing and circumferential pre-biliary fibrosis pathogenesis. The secretion of chemokines and cytokines by innate immune cells and inflammatory and fibrotic response to toxic bile leaking between inured cholangiocytes leads to periductal fibrosis.<xref ref-type="bibr" rid="article-27738.r11">[11]</xref></p>
      </sec>
      <sec id="article-27738.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>About 50% of the patients with&#x000a0;PSC are asymptomatic on presentation, and&#x000a0;they are diagnosed after abnormal&#x000a0;liver function tests are found when tested for other reasons. Most patients are males in the third or fourth decade of life. Most patients complain of right upper quadrant abdominal pain (20%) and pruritus (10%), which might be episodic, fatigue, and jaundice (6%).&#x000a0;Pruritus can be extremely disabling, leading to severe excoriations and a decreased quality of life. Weight loss&#x000a0;may also be reported at the presentation. Late symptoms or symptoms of advanced liver disease include jaundice, gastrointestinal bleeding, ascites, and confusion. Physical examination may reveal hepatomegaly&#x000a0;(44% of patients), splenomegaly (39%), jaundice, and excoriations from pruritus. The development of fever, chills, and right upper quadrant pain&#x000a0;with or without jaundice&#x000a0;indicates&#x000a0;the development of&#x000a0;bacterial cholangitis, which may occur sporadically.</p>
      </sec>
      <sec id="article-27738.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Liver biochemical tests usually demonstrate a cholestatic pattern, with an elevation of the serum alkaline phosphatase&#x000a0;being a characteristic finding. The elevation of transaminases (aspartate&#x000a0;transaminase and alanine transaminase) is modest&#x000a0;at 2 to 3 times the upper limit of normal. Bilirubin and albumin levels may be normal at diagnosis but become increasingly abnormal as the disease progresses.&#x000a0;Elevated serum bilirubin levels suggest the possibility of more advanced&#x000a0;disease, dominant biliary strictures, or cirrhosis.</p>
        <p>Atypical perinuclear antineutrophil&#x000a0;cytoplasmic antibodies are positive in about 26% to 94% of patients&#x000a0;with PSC, although they are not specific to the disease. Elevated concentrations of total immunoglobulins (IgM in 50%) may be seen. Positive&#x000a0;antinuclear antibodies and smooth muscle antibodies should alert clinicians to&#x000a0;the possibility of autoimmune hepatitis-related PSC or overlap syndromes. Immunoglobulin subsets&#x000a0;elevation&#x000a0;(IgG4 in 10%) may also be seen.&#x000a0;Serum IgG4 elevations&#x000a0;are not specific to IgG4-related diseases. Serum IgG4 levels of&#x000a0;more than&#x000a0;4 times the upper limit of normal or IgG4:IgG1&#x000a0;ratio of more than 0.24 strongly&#x000a0;suggest IgG4-associated PSC.<xref ref-type="bibr" rid="article-27738.r10">[10]</xref></p>
        <p>Imaging, usually with ultrasound or computed&#x000a0;tomography, may be&#x000a0;performed in patients with persistent cholestatic liver tests to exclude biliary obstruction. The diagnosis of PSC is typically made with the demonstration of characteristic multiple and focal areas of stricturing and dilation of intrahepatic&#x000a0;or&#x000a0;extrahepatic bile ducts on cholangiography. A cholangiogram may be obtained using magnetic resonance cholangiopancreatography (MRCP), ERCP, or percutaneous transhepatic cholangiography (PTC).&#x000a0;MRCP is usually the first test of choice. Because ERCP is an&#x000a0;invasive&#x000a0;procedure,&#x000a0;and the diagnostic&#x000a0;accuracy of MRCP is comparable to ERCP, MRCP is preferred over ERCP. PTC is reserved for patients who are not able to undergo MRCP, for example, those with implanted metal devices) or ERCP.</p>
        <p>A liver biopsy is usually not needed for diagnosis unless it overlaps with autoimmune hepatitis or a small-duct PSC is suspected. Noninvasive diagnostic tools that assess fibrosis, like magnetic resonance&#x000a0;elastography&#x000a0;and transient&#x000a0;elastography&#x000a0;of the liver,&#x000a0;are&#x000a0;promising. Still, their specific role in&#x000a0;evaluating&#x000a0;the degree of&#x000a0;liver fibrosis in patients with&#x000a0;PSC is unclear.<xref ref-type="bibr" rid="article-27738.r8">[8]</xref>&#x000a0;Diagnostic criteria for the diagnosis of PSC include:</p>
        <list list-type="order">
          <list-item>
            <p>An increased serum alkaline phosphatase level that persists for more than&#x000a0;6 months</p>
          </list-item>
          <list-item>
            <p>Cholangiographic findings of bile-duct strictures detected using either MRCP or ERCP</p>
          </list-item>
          <list-item>
            <p>Exclusion of causes of secondary sclerosing cholangitis</p>
          </list-item>
        </list>
        <p>The key feature in histology is periductal or onion skin fibrosis.</p>
      </sec>
      <sec id="article-27738.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of&#x000a0;PSC is challenging&#x000a0;and complex. There is no established treatment for PSC yet.&#x000a0;Ursodeoxycholic acid (UDCA)&#x000a0;has been widely studied as a therapy for PSC patients. Treatment guidelines for PSC are conflicting. American College of Gastroenterology and the American Association for the Study of Liver Diseases do not support using ursodeoxycholic acid. The European Association has approved using moderate doses of ursodeoxycholic acid for the Study of the Liver.&#x000a0;Nonetheless, it remains widely used at moderate doses of 15 to 20 mg/kg daily.<xref ref-type="bibr" rid="article-27738.r10">[10]</xref><xref ref-type="bibr" rid="article-27738.r12">[12]</xref>&#x000a0;A few studies do show that UDCA can improve symptoms and survival.</p>
        <p>Other treatments&#x000a0;that have been tested and are not proven&#x000a0;to be beneficial are&#x000a0;prednisolone, budesonide, colchicine, penicillamine,&#x000a0;azathioprine, tacrolimus, methotrexate, mycophenolate mofetil, and antitumor&#x000a0;necrosis factor antibodies. In patients with PSC with dominant stricture (defined as stenoses measuring less than 1.5 mm in the common bile duct or less than 1.0 mm in the hepatic ducts) and pruritus or cholangitis, ERCP with balloon dilatation is recommended to relieve symptoms.</p>
        <p>Surgical options for PSC include biliary reconstructive procedures like&#x000a0;choledochoduodenostomy, in which the surgeon attaches the common bile duct to the duodenum, and choledochojejunostomy, in which the surgeon&#x000a0;attaches the common bile duct to the jejunum, and liver transplantation.&#x000a0;Liver transplantation is the definitive treatment for patients with decompensated cirrhosis.&#x000a0;Patients whose model for end-stage liver disease score exceeds 14 should&#x000a0;be referred for liver transplantation. Orthotopic liver transplantation has 5-year survival rates of up to 80% in patients with PSC.<xref ref-type="bibr" rid="article-27738.r12">[12]</xref></p>
        <p>
<bold>General Measures</bold>
</p>
        <p>Bile acid sequestrants such as cholestyramine should be taken to reduce symptoms in patients with PSC and moderate pruritus.&#x000a0;Rifampin&#x000a0;and naltrexone are second-line treatment agents, which&#x000a0;can&#x000a0;be considered if cholestyramine is ineffective or poorly tolerated. Patients with PSC should undergo bone mineral density testing at the time of diagnosis and then every 2 to&#x000a0;4 years. Fat-soluble&#x000a0;vitamin deficiencies are common in patients&#x000a0;with&#x000a0;advanced&#x000a0;liver disease; clinicians should screen for and monitor patients for these.</p>
      </sec>
      <sec id="article-27738.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for&#x000a0;primary sclerosing cholangitis includes:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Secondary sclerosing cholangitis:</italic> Secondary causes of PSC include chronic bacterial cholangitis, cholangiocarcinoma, choledocholithiasis, recurrent pancreatitis, and surgical biliary trauma.</p>
          </list-item>
          <list-item>
            <p>IgG4-associated cholangitis</p>
          </list-item>
          <list-item>
            <p>PSC-autoimmune hepatitis overlap syndrome is typically seen in children and young adults</p>
          </list-item>
          <list-item>
            <p>Histiocytosis X</p>
          </list-item>
          <list-item>
            <p>HIV syndrome</p>
          </list-item>
          <list-item>
            <p>Bile duct strictures</p>
          </list-item>
          <list-item>
            <p>Primary biliary cirrhosis</p>
          </list-item>
          <list-item>
            <p>Papillary tumors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27738.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The common history of&#x000a0;PSC is highly variable and unpredictable. A persistently low serum alkaline phosphatase level of less than 1.5 times the upper limit of normal confers a good prognosis.<xref ref-type="bibr" rid="article-27738.r13">[13]</xref>&#x000a0;Patients with<italic toggle="yes">&#x000a0;</italic>small duct&#x000a0;PSC have a good prognosis, with no reports of bile duct malignancy in this group, and progression to advanced liver disease is uncommon. The Mayo risk score, which&#x000a0;includes age, serum bilirubin, serum albumin, serum AST, and history of variceal bleeding, helps predict survival in patients with PSC.<xref ref-type="bibr" rid="article-27738.r14">[14]</xref></p>
      </sec>
      <sec id="article-27738.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The following are some significant complications of PSC:</p>
        <list list-type="order">
          <list-item>
            <p>Fat-soluble&#x000a0;A, D, E, and K&#x000a0;vitamin deficiencies</p>
          </list-item>
          <list-item>
            <p>Metabolic bone disease (osteoporosis)</p>
          </list-item>
          <list-item>
            <p>Cholangiocarcinoma</p>
          </list-item>
          <list-item>
            <p>Gallbladder cancer&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dominant biliary strictures</p>
          </list-item>
          <list-item>
            <p>Cholangitis</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma in patients with cirrhosis.<xref ref-type="bibr" rid="article-27738.r15">[15]</xref>&#x000a0;Hepatic fibrosis progressively develops in these patients, leading to cirrhosis and hepatocellular carcinoma.</p>
          </list-item>
          <list-item>
            <p>Colon cancer in patients with concomitant ulcerative colitis. Surveillance with colonoscopy should be performed annually in these patients who have concomitant PSC and IBD.<xref ref-type="bibr" rid="article-27738.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Cholelithiasis</p>
          </list-item>
          <list-item>
            <p>Portal hypertension</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27738.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Patients with steatorrhea should be maintained on medium-chain triglycerides. Some patients may even need pancreatic enzyme supplements. Physical activity should be encouraged, but caution should be exercised in patients with osteoporosis because of the risk of fracture. Patients should undergo a colonoscopy to rule out inflammatory bowel disease in the long term. Serum levels of CA 19.9 should be followed to screen for cholangiocarcinoma.</p>
      </sec>
      <sec id="article-27738.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Following are the important consultations that are usually needed while managing a patient with PSC:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastroenterology</p>
          </list-item>
          <list-item>
            <p>Surgery</p>
          </list-item>
          <list-item>
            <p>Hepatologists</p>
          </list-item>
          <list-item>
            <p>Transplant team</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27738.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>There is no definite cure for&#x000a0;PSC at the time of this writing. Significant advances have been made in the early diagnosis of PSC, however, which is essential so that treatment can be started before developing liver failure.</p>
      </sec>
      <sec id="article-27738.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The treatment of&#x000a0;PSC requires an interprofessional approach. Gastroenterology&#x000a0;consultation is useful. Surgery consult and referral to a&#x000a0;tertiary&#x000a0;center&#x000a0;are needed in patients undergoing liver transplantation. Patients with osteoporosis might need to be referred to an endocrinologist. Besides physicians, nurses, dieticians, psychiatric counselors, pharmacists, and physical therapists play a critical role in managing these patients.&#x000a0;Pharmacists should encourage patients to take appropriate&#x000a0;medications and educate patients about their&#x000a0;side effects. Patients need to be evaluated by a dietician for appropriate&#x000a0;diet recommendations. Gastroenterology nurses provide education, monitor patient status, and facilitate referrals. The transplant nurse should assess the patient's candidacy for a transplant and assist the team by educating the patient on the surgery. Physical therapy is encouraged except in patients with advanced osteoporosis. Some patients might benefit from psychiatric counseling. Close communication between team members is essential for improving outcomes.</p>
      </sec>
      <sec id="article-27738.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27738&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27738">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/primary-sclerosing-cholangitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27738">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27738/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27738">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27738.s18">
        <title>References</title>
        <ref id="article-27738.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angulo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Primary sclerosing cholangitis.</article-title>
            <source>Hepatology</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>325</fpage>
            <page-range>325-32</page-range>
            <pub-id pub-id-type="pmid">10385674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tischendorf</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kr&#x000fc;ger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-14</page-range>
            <pub-id pub-id-type="pmid">17037993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazaridis</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>The Cholangiopathies.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>791</fpage>
            <page-range>791-800</page-range>
            <pub-id pub-id-type="pmid">25957621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sunkara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.</article-title>
            <source>J Inflamm Res</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>215</fpage>
            <page-range>215-226</page-range>
            <pub-id pub-id-type="pmid">29844695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fevery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalloo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagorney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Boberg</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Shneider</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gores</surname>
                <given-names>GJ</given-names>
              </name>
              <collab>American Association for the Study of Liver Diseases</collab>
            </person-group>
            <article-title>Diagnosis and management of primary sclerosing cholangitis.</article-title>
            <source>Hepatology</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>660</fpage>
            <page-range>660-78</page-range>
            <pub-id pub-id-type="pmid">20101749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boonstra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ponsioen</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.</article-title>
            <source>J Hepatol</source>
            <year>2012</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1181</fpage>
            <page-range>1181-1188</page-range>
            <pub-id pub-id-type="pmid">22245904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molodecky</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kareemi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parab</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barkema</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis.</article-title>
            <source>Hepatology</source>
            <year>2011</year>
            <month>May</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>1590</fpage>
            <page-range>1590-9</page-range>
            <pub-id pub-id-type="pmid">21351115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazaridis</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Primary Sclerosing Cholangitis.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>22</day>
            <volume>375</volume>
            <issue>12</issue>
            <fpage>1161</fpage>
            <page-range>1161-70</page-range>
            <pub-id pub-id-type="pmid">27653566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlsen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hov</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Balschun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bergquist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weism&#x000fc;ller</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gotthardt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rust</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Philipp</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Henckaerts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weersma</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Stokkers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ponsioen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wijmenga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sterneck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nothnagel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hampe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teufel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Runz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenstiel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stiehl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schrumpf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boberg</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association analysis in primary sclerosing cholangitis.</article-title>
            <source>Gastroenterology</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>1102</fpage>
            <page-range>1102-11</page-range>
            <pub-id pub-id-type="pmid">19944697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DEJ</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary sclerosing cholangitis.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>23</day>
            <volume>391</volume>
            <issue>10139</issue>
            <fpage>2547</fpage>
            <page-range>2547-2559</page-range>
            <pub-id pub-id-type="pmid">29452711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fickert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pollheimer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lackner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Housset</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keitel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Karlsen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Melum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eksteen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strazzabosco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <collab>International PSC Study Group (IPSCSG)</collab>
            </person-group>
            <article-title>Characterization of animal models for primary sclerosing cholangitis (PSC).</article-title>
            <source>J Hepatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>1290</fpage>
            <page-range>1290-303</page-range>
            <pub-id pub-id-type="pmid">24560657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>ME</given-names>
              </name>
              <collab>American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: Primary Sclerosing Cholangitis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2015</year>
            <month>May</month>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>646</fpage>
            <page-range>646-59; quiz 660</page-range>
            <pub-id pub-id-type="pmid">25869391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williamson</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Primary sclerosing cholangitis: a clinical update.</article-title>
            <source>Br Med Bull</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-64</page-range>
            <pub-id pub-id-type="pmid">25981516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Poterucha</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Malinchoc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>A revised natural history model for primary sclerosing cholangitis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>75</volume>
            <issue>7</issue>
            <fpage>688</fpage>
            <page-range>688-94</page-range>
            <pub-id pub-id-type="pmid">10907383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sunkara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Muralidharan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Update in global trends and aetiology of hepatocellular carcinoma.</article-title>
            <source>Contemp Oncol (Pozn)</source>
            <year>2018</year>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>141</fpage>
            <page-range>141-150</page-range>
            <pub-id pub-id-type="pmid">30455585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27738.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mowat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Windsor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arnott</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Driscoll</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rutter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Younge</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Satsangi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>S</given-names>
              </name>
              <collab>IBD Section of the British Society of Gastroenterology</collab>
            </person-group>
            <article-title>Guidelines for the management of inflammatory bowel disease in adults.</article-title>
            <source>Gut</source>
            <year>2011</year>
            <month>May</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>571</fpage>
            <page-range>571-607</page-range>
            <pub-id pub-id-type="pmid">21464096</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
